Microbial Fermentation APIs Market By Type (Antibiotics, Amino Acids, Vitamin, Nucleotide, Organic Acid, Alcohol, Biological Products, and Hormone), By Application (Hospitals, Research & Academic Laboratories, and Pharmaceutical & Biotechnology Companies), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI117219 | Publish Date: April 2024 | No. of Pages: 180

Global Microbial Fermentation APIS Market Overview

Microbial Fermentation APIS Market accounted for USD 65.3 Billion in 2024 and is estimated to be USD 14.3 Billion by 2034 and is anticipated to register a CAGR of 9.0%.

Microbial fermentation is a biochemical process of breaking down of large organic molecules to smaller ones  via the action of microorganism such as bacteria,  to produce compound of interest. In the pharmaceutical industry, this process is often employed to produce APIs, which are the active ingredients in medications. Safer and more effective medicines are provided when fermentation technique is combined with current molecular biology technologies or genetic engineering tools.

Global Microbial Fermentation APIS Market Drivers & Restraints

Drivers

Restrains

Rising Demands for Biological Drugs

Competitive Landscape

Ease of Development

High Initial Investment

Cost- Effective

Scale-Up Challenges

Non-toxic, Ready availability

 
Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Microbial Fermentation APIS Market Segmentations & Regional Insights

Dividing this target market into segments:

Microbial Fermentation APIs Market is segmented based on Type, Application and Region.

Type Insight

On the basis of Type, the target market is segmented into Antibiotics, Amino Acids, Vitamin, Nucleotide, Organic Acid, Alcohol, Biological Products, and Hormone

Application Insight

On the basis of Application, the target market is segmented into Hospitals, Research & Academic Laboratories, and Pharmaceutical & Biotechnology Companies

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Type – Antibiotics, Amino Acids, Vitamin, Nucleotide, Organic Acid, Alcohol, Biological Products, and Hormone

By Application - Hospitals, Research & Academic Laboratories, and Pharmaceutical & Biotechnology Companies

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034.

Global Microbial Fermentation APIS Market Competitive Landscape & Key Players

The key players operating the Microbial Fermentation APIs Market includes, Merck & Co, Inc., Ajinomoto Inc., HGPF, Huaxing Co, Ltd., North China Pharmaceutical Inc., Henan Topfond Pharmaceutical Co, Ltd., DSM B.V, Tianyao Pharmacutical Co, Ltd., and CSPC Pharmaceutical Group Ltd.

Global Microbial Fermentation APIS Market Recent News

The New Launched Product News,

  • In October 2022, BIOVECTRA announced expansion of its manufacturing Capacity with Single-Use Microbial Fermentation Technology. This move will increase customer flexibility, turnaround times, and capacity utilization. Single-use sterile fermenters are designed to facilitate mixing, oxygen transfer, and chilling. They offer a distinct alternative and a noteworthy advantage over fermenters made of stainless steel with respect to batch segregation and cross-contamination risks.
  • In November 2022, Antheia, a science and technology company, announced that they are  developing next generation plant-inspired medicines using fermentation to produce complex active pharmaceutical ingredients (APIs) that have so far only been attainable via botanical sources. By creating a pathway to produce APIs with fermentation, Antheia aims to enable more resilient, sustainable supply chains for drugs and essential medicines.

Global Microbial Fermentation APIS Market Company Profile

FAQs

The challenges in scaling up microbial fermentation processes for large-scale production, leading to operational complexities and cost considerations.

Restraints of the Microbial Fermentation APIS Market include limitations in handling high-viscosity fluids and challenges in maintaining uniform mixing at higher volumes.

Growing demand for sustainable and cost-effective manufacturing processes in the pharmaceutical industry

By region, the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.

Merck & Co, Inc., Ajinomoto Inc., HGPF, Huaxing Co, Ltd., North China Pharmaceutical Inc., Henan Topfond Pharmaceutical Co, Ltd., DSM B.V, Tianyao Pharmacutical Co, Ltd., and CSPC Pharmaceutical Group Ltd.